Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Intralesional Administration
Email alerts
Intralesional Administration
Innate and adaptive immunity contribute to the anti-tumor mechanisms of action of OncoVEX
mGM-CSF
Keegan
Cooke
,
Karen
Fitzgerald
,
Becky
Yang
,
Petia
Mitchell
,
Juan
Estrada
,
Beltran
Pedro
,
Achim K
Moesta
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P338;
DOI:
10.1186/2051-1426-3-S2-P338
Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment
Robert HI
Andtbacka
,
Brendan D
Curti
,
Sigrun
Hallmeyer
,
Zipei
Feng
,
Christopher
Paustian
,
Carlo
Bifulco
,
Bernard
Fox
,
Mark
Grose
,
Darren
Shafren
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(Suppl 2)
P343;
DOI:
10.1186/2051-1426-3-S2-P343
Talilmogene Iaherparepvec generates systemic T-cell-mediated anti-tumor immunity
Julia
Piasecki
,
Le
Tiep
,
Jean
Zhou
,
Courtney
Beers
Journal for ImmunoTherapy of Cancer
Nov 2013,
1
(Suppl 1)
P198;
DOI:
10.1186/2051-1426-1-S1-P198
Special collections
COVID-19
(44)
Editor's choice
JITC
Basic Tumor Immunology
(531)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(930)
Commentary/Editorials
(139)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(53)
Guidelines and Consensus Statements
(50)
Imaging and Immunotherapy
(8)
Immune Cell Therapies and Immune Cell Engineering
(208)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(401)
Liquid Biopsies
(9)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(142)
Reviews
(238)
Open access
(4833)
Press releases